Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Company Deals

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market

Fineline Cube Apr 14, 2026
Company Deals

Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech

Fineline Cube Apr 14, 2026
Company Deals

Zuellig Pharma Acquires Cialis Rights for Hong Kong, Macau, and South Korea from Eli Lilly

Fineline Cube Apr 14, 2026
Company Deals

Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration

Fineline Cube Apr 14, 2026
Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Fineline Cube Apr 14, 2026
Company Drug

Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion

Fineline Cube Apr 14, 2026
Company Drug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Fineline Cube Apr 14, 2026
Company Deals Drug

Zhaoke Ophthalmology Partners with AFT for Brimochol PF Distribution in ANZ

Fineline Cube Jan 14, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a strategic distribution and supply agreement with...

Company Drug

Tonghua Dongbao Begins Phase II Trial for GLP-1/GIP Agonist THDBH120 in Weight Loss

Fineline Cube Jan 14, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced a significant milestone in its clinical development...

Company Deals

Neo Modulus Secures $40.9M Series C Funding for Regenerative Medical Devices

Fineline Cube Jan 14, 2025

Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd., a prominent developer of regenerative implantable medical devices...

Company Deals

MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors

Fineline Cube Jan 14, 2025

Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...

Company Deals

Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500

Fineline Cube Jan 14, 2025

China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its...

Company Drug

CSPC’s Prusogliptin Approved in China for Type 2 Diabetes Treatment

Fineline Cube Jan 14, 2025

China’s National Medical Products Administration (NMPA) has granted marketing approval to CSPC Pharmaceutical Group Co.,...

Company Deals

3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303

Fineline Cube Jan 14, 2025

China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a...

Company Deals Medical Device

CBC Group’s R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion

Fineline Cube Jan 14, 2025

CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in...

Company Drug

JW Therapeutics’ Carteyva Granted Breakthrough Therapy Designation by CDE

Fineline Cube Jan 13, 2025

China-based JW Therapeutics (HKG: 2126) has announced that its Carteyva (relmacabtagene autoleucel injection) has been...

Company Drug

CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval

Fineline Cube Jan 13, 2025

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has reported significant progress in its antibody...

Company Deals

Suzhou Ribo and Boehringer Ingelheim Reach Pre-Clinical Milestone in NASH/MASH Partnership

Fineline Cube Jan 13, 2025

China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...

Company Medical Device

Johnson & Johnson MedTech’s Dual Energy Catheter Gains CE Mark

Fineline Cube Jan 13, 2025

US major Johnson & Johnson MedTech has announced that its Dual Energy THERMOCOOL SMARTTOUCH SF...

Company Drug

Henlius Biotech Gains NMPA Clearance for HLX43 ADC Study

Fineline Cube Jan 13, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clearance from...

Company Deals

Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development

Fineline Cube Jan 13, 2025

China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal...

Company Deals Drug

Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases

Fineline Cube Jan 13, 2025

US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology...

Company Drug

Junshi Biosciences’ Mindewei Receives Full Approval in China

Fineline Cube Jan 13, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the conditional...

Company Drug

Ucello Biotech’s UC101 Receives FDA IND Clearance for Anti-CD19 Therapy

Fineline Cube Jan 13, 2025

China-based Chengdu Ucello Biotechnology Co., Ltd., a developer of allogeneic universal chimeric antigen receptor (CAR)-T...

Company Deals

Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio

Fineline Cube Jan 13, 2025

Chinese firms Harbour BioMed (HKG: 2142) and Sichuan Kelun Biotech BioPharmaceutical (HKG: 6990) have entered...

Company Drug

Hengrui’s Recaticimab Approved for Hypercholesterolemia Treatment

Fineline Cube Jan 13, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its Category 1 biologic...

Company Deals

HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics

Fineline Cube Jan 13, 2025

China-based Hangzhou HealZen Therapeutics Co., Ltd., in collaboration with the Shanghai Institute of Materia Medica,...

Posts pagination

1 … 212 213 214 … 650

Recent updates

  • Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion
  • China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access
  • Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion
  • China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program
  • CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion

Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Company Drug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.